Search results for Palivizumab ELISA Kit

Palivizumab ELISA Kit, ProteoGenix, PXZ

Palivizumab ELISA Kit, ProteoGenix, KPTX284

Description of Palivizumab ELISA Kit Introduction to Palivizumab ELISA Kit Palivizumab ELISA Kit is a highly sensitive and specific diagnostic tool used for the detection of Palivizumab, a monoclonal antibody, in biological samples. This kit is widely used in research and clinical settings to measure the levels of Palivizumab in patient samples, making it an essential tool for therapeutic target identification and monitoring. Structure of Palivizumab ELISA Kit The Palivizumab ELISA Kit is based on the principle of Enzyme-Linked Immunosorbent Assay (ELISA). It consists of a 96-well microplate coated with a specific anti-Palivizumab antibody. The kit also includes a set of standards, controls, and reagents necessary for the assay. The Palivizumab ELISA Kit is a sandwich ELISA, where the captured antibody on the microplate binds to Palivizumab in the sample, forming a complex. This complex is then detected by a second enzyme-labeled antibody specific for Palivizumab. The intensity of the color produced is directly proportional to the amount of Palivizumab present in the sample. Activity of Palivizumab ELISA Kit The Palivizumab ELISA Kit has a high sensitivity and specificity, with a detection limit of 0.5 ng/mL. This allows for accurate and precise quantification of Palivizumab levels in various biological samples, including serum, plasma, and cell culture supernatants. The assay can be completed within 3 hours, making it a time-efficient tool for high-throughput screening. It also has a wide dynamic range, allowing for the detection of both low and high levels of Palivizumab in samples. Application of Palivizumab ELISA Kit The Palivizumab ELISA Kit has various applications in both research and clinical settings. It is primarily used for the evaluation of Palivizumab therapy in patients with respiratory syncytial virus (RSV) infection. RSV is a common cause of respiratory tract infections, especially in infants and young children. Palivizumab is an FDA-approved monoclonal antibody used for the prevention of severe RSV infection in high-risk infants. In research, the Palivizumab ELISA Kit is used for the identification and validation of Palivizumab as a therapeutic target for RSV infection. It is also used for the measurement of Palivizumab levels in preclinical studies to assess its pharmacokinetics and pharmacodynamics. In clinical settings, the Palivizumab ELISA Kit is used to monitor the levels of Palivizumab in patients undergoing therapy. This allows for the optimization of dosing and ensures that patients are receiving the appropriate amount of Palivizumab for effective treatment. Conclusion The Palivizumab ELISA Kit is a valuable tool for the detection and quantification of Palivizumab in various biological samples. Its high sensitivity, specificity, and wide dynamic range make it a reliable and efficient method for Palivizumab analysis. With its various applications in research and clinical settings, the Palivizumab ELISA Kit plays a crucial role in the development and monitoring of Palivizumab therapy for RSV infection.

Palivizumab ELISA Kit, Abbexa, abx395173

Palivizumab ELISA Kit is a quantitative ELISA kit for detection of Palivizumab.Palivizumab (brand name Synagis) is a humanized IgG monoclonal antibody (mAb) manufactured by MedImmune with recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab directed against an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cκ and the variable framework regions of the VL gene K104 with Jκ -4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy chains and two light chains and has a molecular weight of approximately 148,000 Daltons. Palivizumab was approved for medical use in 1998 but the indications for prophylaxis vary worldwide. Palivizumab is primarily indicated for the following conditions: prematurity (gestational age ≤ 35 weeks), bronchopulmonary dysplasia/chronic lung disease, hemodynamically significant congenital heart disease, and other serious medical disorders on an ad hoc basis. Infants with these medical conditions are at increased risk of more severe disease and more serious subsequent sequelae.